Rationale for immunotherapy of renal cell carcinoma

Urological Research
R Heicappell, R Ackermann

Abstract

Metastasis to distant organs is the principal cause of death from renal cell carcinoma (RCC). No commonly accepted therapy is available for disseminated RCC at present. Immunotherapy is a mode of therapy that either interferes with the immune system or makes use of drugs that have been derived from soluble mediators of the immune system. Several lines of evidence suggest that combinations of genetically engineered cytokines (e.g. interleukin-2 and interferon alpha) may be particularly active in the treatment of advanced RCC. There are two major rationales for considering immunotherapy for RCC: (1) there is currently no other therapy available, and (2) there is hardly any innovative approach besides immunotherapy. Still, immunotherapy is far from being a standard therapy for disseminated RCC.

References

Aug 1, 1978·The Journal of Urology·J B DekernionR B Smith
Sep 1, 1975·Proceedings of the National Academy of Sciences of the United States of America·E A CarswellB Williamson
Apr 1, 1975·Pathology·V J McGovern
Jun 7, 1990·The New England Journal of Medicine·T van der PollJ W ten Cate
Oct 15, 1986·International Journal of Cancer. Journal International Du Cancer·E OosterwijkS O Warnaar
Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A T FojoI Pastan
Jun 2, 1988·The New England Journal of Medicine·T C Merigan
Jan 1, 1989·Advances in Immunology·C A Dinarello
Nov 1, 1989·The Journal of Urology·J S Horoszewicz, G P Murphy
Feb 1, 1989·American Journal of Clinical Oncology·M R SertoliR Rosso
Jun 1, 1989·The Journal of Experimental Medicine·P BrouckaertW Fiers
Jan 1, 1989·The Journal of Experimental Medicine·J Van SnickR J Simpson
Feb 15, 1989·International Journal of Cancer. Journal International Du Cancer·J van DijkR L Bolhuis
Jan 18, 1989·Journal of the National Cancer Institute·L J GoldsteinG M Brodeur
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M M Gottesman, I Pastan
Apr 29, 1989·Lancet·A O'Garra
May 6, 1989·Lancet·A O'Garra
Jan 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·R G GoodwinA E Namen
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Frei, D Spriggs
Feb 24, 1989·Deutsche medizinische Wochenschrift·F Herrmann, R Mertelsmann
Apr 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K A MargolinM Roper
Jan 1, 1989·Journal of Cancer Research and Clinical Oncology·B WiedenmannB Kommerell
Jan 1, 1989·Urologia Internationalis·T SchärfeR Hohenfellner
Sep 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E Salmon, R Liu
Jan 1, 1989·Cancer Immunology, Immunotherapy : CII·T MoritzC G Schmidt
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R B Herberman
Jan 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R E LeeS A Rosenberg
Feb 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S P CreekmoreR I Fisher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.